Christopher Benecchi
Corporate Officer/Principal chez SAGE THERAPEUTICS, INC.
Fortune : 364 118 $ au 31/03/2024
Profil
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019.
Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0,03% | 13/02/2024 | 19 430 ( 0,03% ) | 364 118 $ | 31/03/2024 |
Postes actifs de Christopher Benecchi
| Sociétés | Poste | Début |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Corporate Officer/Principal | 21/09/2021 |
Anciens postes connus de Christopher Benecchi
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2021 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01/08/2019 |
Formation de Christopher Benecchi
| Duke University | Masters Business Admin |
| Colby College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SAGE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
